NxStage Medical, Inc.  

(Public, NASDAQ:NXTM)   Watch this stock  
Find more results for NXTM
13.87
+0.27 (1.99%)
May 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.52 - 13.95
52 week 10.15 - 17.15
Open 13.52
Vol / Avg. 288,642.00/308,204.00
Mkt cap 828.55M
P/E     -
Div/yield     -
EPS -0.26
Shares 59.74M
Beta 0.59
Inst. own 84%
Aug 5, 2013
Q2 2013 NxStage Medical, Inc. Earnings Release Add to calendar
Jun 18, 2013
NxStage Medical, Inc. at Wells Fargo Health Care Conference - 4:05PM EDT - Add to calendar
Jun 12, 2013
NxStage Medical, Inc. at William Blair Growth Stock Conference - 2:20PM EDT - Add to calendar
May 23, 2013
NxStage Medical, Inc. Annual Stockholders Meeting
May 6, 2013
Q1 2013 NxStage Medical, Inc. Earnings Release
May 2, 2013
Q1 2013 NxStage Medical, Inc. Earnings Conference Call
Feb 28, 2013
Q4 2012 NxStage Medical, Inc. Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -8.10% -6.26%
Operating margin -7.36% -4.63%
EBITD margin - 6.31%
Return on average assets -6.42% -5.02%
Return on average equity -10.16% -8.69%
Employees 2,700 -
Carbon Disclosure Rating - -

Address

350 Merrimack Street
LAWRENCE, MA 01843
United States - Map
+1-978-6874700 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company�s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.

Officers and directors

Jeffrey H. Burbank Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Robert S. Brown Chief Financial Officer, Senior Vice President, Treasurer
Age: 54
Bio & Compensation  - Reuters
Joseph E. Turk Jr. President - North American Operations
Age: 45
Bio & Compensation  - Reuters
Winifred L. Swan Senior Vice President, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
Thomas F. Shea Senior Vice President - Manufacturing Operations
Age: 50
Bio & Compensation  - Reuters
Todd M. Snell Senior Vice President - Quality Assurance, Regulatory & Clinical Affairs
Age: 42
Bio & Compensation  - Reuters
Robert G. Funari Non-Executive Chairman of the Board
Bio & Compensation  - Reuters
Jean K. Mixer Director
Bio & Compensation  - Reuters
Daniel A. Giannini Independent Director
Age: 62
Bio & Compensation  - Reuters
Earl R. Lewis Independent Director
Age: 69
Bio & Compensation  - Reuters